VIADUR Drug Patent Profile

✉ Email this page to a colleague

When do Viadur patents expire, and when can generic versions of Viadur launch?

Viadur is a drug marketed by Ortho Mcneil Janssen and is included in one NDA.

The generic ingredient in VIADUR is leuprolide acetate. There are twenty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the leuprolide acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viadur

A generic version of VIADUR was approved as leuprolide acetate by SANDOZ on August 4^th, 1998.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for VIADUR?
What are the global sales for VIADUR?
What is Average Wholesale Price for VIADUR?

Summary for VIADUR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	57
Clinical Trials:	20
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIADUR
DailyMed Link:	VIADUR at DailyMed

Drug patent expirations by year for VIADUR

Recent Clinical Trials for VIADUR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
NRG Oncology	Phase 2
ECOG-ACRIN Cancer Research Group	Phase 3
Jonsson Comprehensive Cancer Center	Phase 2

See all VIADUR clinical trials

US Patents and Regulatory Information for VIADUR

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ortho Mcneil Janssen	VIADUR	leuprolide acetate	IMPLANT;IMPLANTATION	021088-001	Mar 3, 2000		DISCN	No	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for VIADUR

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Ortho Mcneil Janssen	VIADUR	leuprolide acetate	IMPLANT;IMPLANTATION	021088-001	Mar 3, 2000	⤷ Sign Up	⤷ Sign Up
Ortho Mcneil Janssen	VIADUR	leuprolide acetate	IMPLANT;IMPLANTATION	021088-001	Mar 3, 2000	⤷ Sign Up	⤷ Sign Up
Ortho Mcneil Janssen	VIADUR	leuprolide acetate	IMPLANT;IMPLANTATION	021088-001	Mar 3, 2000	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for VIADUR

See the table below for patents covering VIADUR around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Spain	2182379		⤷ Sign Up
Cyprus	2486	Non-aqueous polar aprotic peptide formulations comprising lhrh-related compounds.	⤷ Sign Up
World Intellectual Property Organization (WIPO)	9933449		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for VIADUR

Recent Clinical Trials for VIADUR

Make Better Decisions: Try a trial or see plans & pricing